An official website of the United States government
A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Trial Status: closed to accrual
The purpose of this study is to learn about the safety and effects of the study medicine
(sasanlimab) in people with non-muscle invasive bladder cancer. This study is seeking
participants whose bladder cancer is still in early stages, has not spread outside of the
bladder, has been removed with surgery, and is high risk (Part A) or was previously
treated with BCG (Bacillus Calmette Guerin), a standard treatment for bladder cancer
(Part B).
In Part A (enrollment closed), each participant was assigned to one of three study
treatment groups.
- One group is given sasanlimab and BCG at the study clinic.
- The second group is given sasanlimab and BCG at the study clinic. This group will
receive BCG for the first six weeks only.
- The third group is given BCG only and will not receive sasanlimab.
In Part B of the study, each new participant will be assigned to a study treatment group
based on the type of their bladder tumor.
- Both groups will be given sasanlimab at the study clinic.
On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B.
The decision to discontinue enrollment to Part B was not made for safety reasons.
Inclusion Criteria
Histological confirmed diagnosis of high risk non-muscle invasive transitional cell carcinoma (TCC) of the urothelium of the urinary bladder (tumors of mixed transitional/non-transitional cell histology are allowed, but TCC must be the predominant histology)
Complete resection of all Ta/T1 papillary disease (including participants with concurrent CIS), with most recent positive TURBT occurring within 12 weeks prior to randomization or study intervention. A second TURBT must have been performed if indicated according to the current locally applicable guidelines, ie, American Urological Association, European Association of Urology
(Cohorts B1 and B2 only): Histological confirmed diagnosis of BCG-unresponsive high-risk, non-muscle invasive TCC of the urothelium within 12 months (CIS only) or 6 months (recurrent Ta/T1 disease) of completion of adequate BCG therapy.
Have refused or are ineligible for radical cystectomy
Exclusion Criteria
Evidence of muscle-invasive, locally advanced or metastatic urothelial cancer or concurrent extravesical, non-muscle invasive TCC of the urothelium
(Cohort A only): Intravesical BCG therapy within 2 years prior to randomization. Prior intravesical chemotherapy for NMIBC is allowed. (Cohorts B1 and B2 only): Any systemic or intravesical chemotherapy or immunotherapy from
the time of most recent positive TURBT to initiation of study intervention.
Prior immunotherapy with anti PD-1, anti PD-L1, anti PD-L2, or anti cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody
Prior treatment with immunostimulatory agents including interleukin (IL)-2, IL-15, interferon (INF)
Prior radiation therapy to the bladder
(Cohorts B1 and B2 only): Prior participation in Cohort A of this study.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04165317.
Locations matching your search criteria
United States
California
San Diego
UC San Diego Medical Center - Hillcrest
Status: Active
Name Not Available
Minnesota
Minneapolis
University of Minnesota/Masonic Cancer Center
Status: Approved
Name Not Available
CREST: Combination of sasanlimab and alternative BCG Regimens to Evaluate outcomes with
Subcutaneous anti-PD-1 Treatment
Phase 3 Design with two Cohorts. Cohort A consists of 3 study Arms (A, B and C) of BCG
naive participants. Arms A and B consist of two study drugs, PF-06801591 plus BCG. Arm C
consists of one study drug, BCG. Cohort B consists of B1 and B2, which test PF-06801591
and include participants who have BCG unresponsive CIS (B1) or BCG unresponsive papillary
only disease (B2).
The study is designed to demonstrate that PF-06801591 plus Bacillus Calmette Guerin (BCG)
(induction and maintenance periods) is superior to BCG alone (induction and maintenance
periods) in prolonging event free survival (EFS) in participants with high-risk naïve
non-muscle invasive bladder cancer (NMIBC) and to demonstrate that PF-06801591 plus BCG
(induction period only) is superior to BCG alone (induction and maintenance periods) in
prolonging EFS in participants with high-risk NMIBC. The study is also designed to
estimate the CR rate of PF-06801591 alone in participants with BCG unresponsive CIS and
to evaluate the EFS of PF-06801591 alone in participants with BCG unresponsive NMIBC.
On August 31, 2022, the Sponsor announced the discontinuation of enrollment to Part B,
which enrolled participants with BCG unresponsive NMIBC. The decision to discontinue
enrollment to Part B was not made for safety reasons.
